Learn how to sew a beautiful kaftan using a simple construction method that requires no placket and no neck piping. This step-by-step guide shows you how to cut, shape, and finish the neckline cleanly ...

EBRD providing financing of up to US$ 20 million to Tashkent Pipe Plant New funds will help to ramp up production of large-diameter pipes Project will introduce new insulation technology and extend ...

This year’s Run~Walk~Smile 5k/10K/1 Mile road races marks the 11th year that the community has come together to ensure that adults with developmental disabilities get the critical dental care they ...

Ofirnoflast’s NEK7 modulation offers a first-in-class anti-inflammatory approach to MDS. The US Food and Drug Administration (FDA) granted Orphan Drug Designation to ofirnoflast (HT-6184) for the ...

Just a boy with big dreams and a whisk in hand! 🍰 Follow Greggy's Digest for fun vlogs, cake design tips, DIY projects, and creative baking hacks. Let’s spread kindness and bake with love! 💖🎂 ...

Editor's Note: This article has been updated to correct the company's ticker symbol. Verizon Communications Inc. (NYSE:VZ) and GE Vernova Inc. (NYSE:GEV) are joining forces to help modernize the ...

Myelodysplastic syndromes (MDS) are a group of disorders in which a person’s bone marrow does not produce enough functioning blood cells. MDS is a type of cancer that damages some of the blood-forming ...

“The Plastics Pipe Institute supports the CIRCLE Act because it strengthens recycling standards, boosts demand for recycled materials, and encourages innovation across our industry,” said David M.

Pipe’s AI agents will significantly advance the company’s operating efficiency, supporting its global expansion while further elevating the customer experience for small businesses. SAN ...

SALT LAKE CITY--(BUSINESS WIRE)--Kindly MD, Inc. (NASDAQ: NAKA) (“KindlyMD”), which previously announced its anticipated merger with Nakamoto Holdings Inc. (“Nakamoto”), a Bitcoin-native holding ...

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r ...